U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H30N2O5
Molecular Weight 438.5171
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of QUINAPRIL

SMILES

CCOC(=O)[C@]([H])(CCc1ccccc1)N[C@@]([H])(C)C(=O)N2Cc3ccccc3C[C@@]2([H])C(=O)O

InChI

InChIKey=JSDRRTOADPPCHY-HSQYWUDLSA-N
InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C25H30N2O5
Molecular Weight 438.5171
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT00651287 | https://www.ncbi.nlm.nih.gov/pubmed/25922179 | https://www.ncbi.nlm.nih.gov/pubmed/1691409

Quinapril is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat. Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents. Quinapril is indicated for the treatment of high blood pressure (hypertension) and as adjunctive therapy in the management of heart failure. It may be used for the treatment of hypertension by itself or in combination with thiazide diuretics, and with diuretics and digoxin for heart failure.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.8 nM [IC50]
110.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACCURETIC

Approved Use

INDICATIONS AND USA. Hypertension: ACCURETIC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ACCURETIC. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. 6 Reference ID: 3818285 Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION). In using ACCURETIC, consideration should be given to the fact that another angiotensinconverting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.

Launch Date

9.4625281E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1526 ng/mL
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
QUINAPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
345 ng/mL
2.5 mg single, intravenous
dose: 2.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
QUINAPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1706 μg × h/L
10 mg 2 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUINAPRILAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2670 ng × h/mL
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
QUINAPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
580 ng × h/mL
2.5 mg single, intravenous
dose: 2.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
QUINAPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.7 h
10 mg 2 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUINAPRILAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.29 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
QUINAPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.26 h
2.5 mg single, intravenous
dose: 2.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
QUINAPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 11
unhealthy, adult
n = 1563
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 1563
Sources: Page: 11
Disc. AE: Headache, Dizziness...
AEs leading to
discontinuation/dose reduction:
Headache (0.7%)
Dizziness (0.8%)
Fatigue (0.3%)
Coughing (0.5%)
Nausea and vomiting (0.3%)
Abdominal pain (0.2%)
Sources: Page: 11
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 12
unhealthy, adult
n = 585
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 585
Sources: Page: 12
Disc. AE: Dizziness, Coughing...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.7%)
Coughing (0.3%)
Fatigue (0.2%)
Nausea and vomiting (0.2%)
Hypotension (0.5%)
Dyspnea (0.2%)
Rash (0.2%)
Sources: Page: 12
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 0.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 11
unhealthy, adult
n = 1563
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 1563
Sources: Page: 11
Fatigue 0.3%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 11
unhealthy, adult
n = 1563
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 1563
Sources: Page: 11
Nausea and vomiting 0.3%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 11
unhealthy, adult
n = 1563
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 1563
Sources: Page: 11
Coughing 0.5%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 11
unhealthy, adult
n = 1563
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 1563
Sources: Page: 11
Headache 0.7%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 11
unhealthy, adult
n = 1563
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 1563
Sources: Page: 11
Dizziness 0.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 11
unhealthy, adult
n = 1563
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 1563
Sources: Page: 11
Dyspnea 0.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 12
unhealthy, adult
n = 585
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 585
Sources: Page: 12
Fatigue 0.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 12
unhealthy, adult
n = 585
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 585
Sources: Page: 12
Nausea and vomiting 0.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 12
unhealthy, adult
n = 585
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 585
Sources: Page: 12
Rash 0.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 12
unhealthy, adult
n = 585
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 585
Sources: Page: 12
Coughing 0.3%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 12
unhealthy, adult
n = 585
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 585
Sources: Page: 12
Hypotension 0.5%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 12
unhealthy, adult
n = 585
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 585
Sources: Page: 12
Dizziness 0.7%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: 12
unhealthy, adult
n = 585
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: M+F
Population Size: 585
Sources: Page: 12
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 6.2 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function.
2001 Apr
Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats.
2001 Apr
Solid-phase extraction and high-performance liquid chromatography applied to the determination of quinapril and its metabolite quinaprilat in urine.
2001 Apr
Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1.
2001 Apr
Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
2001 Apr
[Hypertensive patients with signs of coronary heart disease. An ACE inhibitor improves endothelial function].
2001 Aug 23
Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
2001 Dec
ACE inhibitors for hypertension.
2001 Feb 23
Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
2001 Jan-Feb
Simultaneous determination of hydrochlorothiazide and several inhibitors of angiotensin-converting enzyme by capillary electrophoresis.
2001 Jul 27
Chemical reactivity in solid-state pharmaceuticals: formulation implications.
2001 May 16
Myocardial contractile responsiveness to endothelin-1 in the post-infarction rat model of heart failure: effects of chronic quinapril.
2001 Nov
Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1.
2001 Nov
Modulation of incipient glomerular lesions in experimental diabetic nephropathy by hypotensive and subhypotensive dosages of an ACE inhibitor.
2001 Nov
Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
2001 Nov 1
Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes.
2001 Nov 15
Aminophylline reversal of antihypertensive agent toxicity.
2001 Oct
Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs.
2001 Oct
[Effects of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): double-blind randomized trial].
2001 Sep
Hyperkalemia, renal failure, and converting-enzyme inhibition: an overrated connection.
2001 Sep
Restenotic process and DD genotype after angiotensin-converting enzyme inhibitor treatment.
2001 Sep 1
[Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases].
2002
Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.
2002
Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors.
2002 Aug
Effects of antihypertensive drugs in experimental type 2 diabetes-related nephropathy.
2002 Dec
Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.
2002 Dec
Angiotensin II as an inflammatory mediator: evolving concepts in the role of the renin angiotensin system in the failing heart.
2002 Jan
Determination of the angiotensin-converting enzyme inhibitor quinapril and its metabolite quinaprilat in pharmaceuticals and urine by capillary zone electrophoresis and solid-phase extraction.
2002 Jan
Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension.
2002 Jan
The solid-state stability of amorphous quinapril in the presence of beta-cyclodextrins.
2002 Jan
Simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma using high-performance liquid chromatography with ultraviolet detection.
2002 Jan 25
Subacute and chronic effects of quinapril on cardiac cytokine expression, remodeling, and function after myocardial infarction in the rat.
2002 Jun
Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension.
2002 Mar-Apr
Ventricular remodeling after myocardial infarction and effects of ACE inhibition on hemodynamics and scar formation in SHR.
2002 Mar-Apr
Lowering of blood pressure improves endothelial dysfunction by increase of nitric oxide production in hypertensive rats.
2002 May
Captopril and quinapril reduce reactive oxygen species.
2002 Oct
Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation.
2003 Jan
Effects of angiotensin-converting enzyme inhibition and calcium channel blockade on cardiac apoptosis in rats with 2K1C (two-kidney/one-clip) renovascular hypertension.
2003 Jan
Square wave voltammetric determination of the angiotensin-converting enzyme inhibitors cilazapril, quinapril and ramipril in pharmaceutical formulations.
2003 May
In vitro study on binding interaction of quinapril with bovine serum albumin (BSA) using multi-spectroscopic and molecular docking methods.
2017 Aug
Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.
2017 Feb
Patents

Sample Use Guides

The recommended initial dosage of ACCUPRIL in patients not on diuretics is 10 or 20 mg once daily. Dosage should be adjusted according to blood pressure response measured at peak (2–6 hours after dosing) and trough (predosing). Generally, dosage adjustments should be made at intervals of at least 2 weeks. Most patients have required dosages of 20, 40, or 80 mg/day, given as a single dose or in two equally divided doses.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:10:41 UTC 2021
Edited
by admin
on Sat Jun 26 10:10:41 UTC 2021
Record UNII
RJ84Y44811
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUINAPRIL
INN   MI   USP   VANDF   WHO-DD  
INN  
Official Name English
QUINAPRIL [INN]
Common Name English
QUINAPRIL [WHO-DD]
Common Name English
QUINAPRIL [VANDF]
Common Name English
QUINAPRIL [MI]
Common Name English
QUINAPRIL [USP]
Common Name English
C09AA06
Code English
Classification Tree Code System Code
NDF-RT N0000175562
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
NDF-RT N0000000181
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
WHO-VATC QC09BA06
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
WHO-ATC C09BA06
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
NCI_THESAURUS C247
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
WHO-VATC QC09AA06
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
WHO-ATC C09AA06
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
LIVERTOX 824
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
Code System Code Type Description
LACTMED
Quinapril
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
RXCUI
35208
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY RxNorm
IUPHAR
6350
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
DRUG CENTRAL
2340
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
EVMPD
SUB10201MIG
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
DRUG BANK
DB00881
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
ChEMBL
CHEMBL1592
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
WIKIPEDIA
QUINAPRIL
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
PUBCHEM
54892
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
MERCK INDEX
M9437
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY Merck Index
INN
5780
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
NCI_THESAURUS
C62074
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
FDA UNII
RJ84Y44811
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
CAS
85441-61-8
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
EPA CompTox
85441-61-8
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
MESH
C041125
Created by admin on Sat Jun 26 10:10:42 UTC 2021 , Edited by admin on Sat Jun 26 10:10:42 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC